Trial Profile
A Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial Spondyloarthritis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2015
Price :
$35
*
At a glance
- Drugs Brodalumab (Primary)
- Indications Spondylarthritis
- Focus Therapeutic Use
- Sponsors Amgen
- 18 Jun 2015 Status changed from not yet recruiting to discontinued, as reported by ClinicalTrials.gov.
- 05 May 2015 New trial record